retatrutide phase 2 trial results just delivered the first top-line 3 for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 🚨 HOT OFF THE PRESS:

This does not indicate direct modification of primary aging mechanisms such as genomic instability or telomere attrition

Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R, Bismuth K, Jacques C, Berenbaum F (2022) Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis

Chronic Inflammation : Obesity is linked to systemic inflammation, contributing to atherosclerosis (hardening of the arteries)

Clinically, TIND can manifest with prominent lower extremity weakness while characteristically preserving ankle reflexes, and it has also been reported to produce diabetic lumbosacral radiculoplexus neuropathy characterized by painful asymmetric weakness, findings that parallel the presentation observed in this patient [7,8,9]

However, emerging research and case reports support the biological plausibility of these changes

Week 1 brings minimal side effects for most people